All Categories
| Product Name | Description | Action |
|---|---|---|
| Cetuximab ,Erbitux ,EGFR ,IMC-C225 ,Anti-EGFR monoclonal antibody ,Chimeric IgG1 antibody ,Oncology biologic / Colorectal cancer antibody / Head and neck cancer antibody ,CAS No.205923-56-4 | Trade Name : Erbitux Target : EGFR Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 650(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Aflibercept ,Eylea ,VEGF/PlGF ,Zaltrap ,VEGF-Trap ,Anti-VEGF agent / VEGF inhibitor ,VEGF Trap / VEGF decoy receptor ,Anti-angiogenic agent ,Fusion Protein ,CAS No.862111-32-8 | Trade Name : Eylea Target : VEGF/PlGF Molecular Type : Fusion Protein Sales in 2025 (Millions of USD) : 7770(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Trastuzumab Emtansine ,Kadcyla ,Her2 ,T-DM1 ,Ado-trastuzumab emtansine ,HER2-targeted ADC ,Microtubule inhibitor conjugate ,Non-cleavable linker ADC ,Maytansinoid ADC ,Second-generation ADC | Trade Name : Kadcyla Target : Her2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 2000~2200(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Trastuzumab Deruxtecan ,Enhertu ,Her2 ,DS-8201a ,Fam-trastuzumab deruxtecan-nxki ,Third-generation ADC ,HER2-targeted ADC ,Topoisomerase I inhibitor conjugate ,CAS No.1826843-81-5 | Trade Name : Enhertu Target : Her2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 4500~5000(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Trastuzumab ,Herceptin ,Her2 ,HER2-targeted therapy ,Anti-HER2 monoclonal antibody ,Oncology biologic / Breast cancer antibody ,Monoclonal antibody for HER2-overexpressing tumors ,CAS No.180288-69-1 | Trade Name : Herceptin Target : Her2 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 3000 All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Nivolumab and berahyaluronidase alfa-pmph ,Opdivo SC ,Opdivo Subcutaneous Injection ,Opdivo Qvantig ,BMS-986251 ,Subcutaneous PD-1 inhibitor ,Combination Product (901 and 932) | Trade Name : Opdivo Qvantig® Target : N/A Molecular Type : Combination Product (901 and 932) Sales in 2025 (Millions of USD) : N/A All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Nivolumab and relatlimab-rmbw ,Opdualag Injection ,PD-1, LAG-3 ,BMS-986213 ,PD-1 / LAG-3 dual inhibitor ,Fixed-dose combination immunotherapy ,Fixed-dose Combination (902 and 962) | Trade Name : Opdualag Target : PD-1, LAG-3 Molecular Type : Fixed-dose Combination (902 and 962) Sales in 2025 (Millions of USD) : 1000~1200(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get ... |
|
| Nivolumab ,Opdivo ,PD-1 ,BMS-936558 ,ONO-4538 ,Anti-PD-1 ,Immune Checkpoint Inhibitor ,Monoclonal Antibody ,CAS No. 946414-94-4 | Trade Name : Opdivo Target : PD-1 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 12000 All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
